Published in Invest Ophthalmol Vis Sci on February 23, 2011
Acrylamide inhibits nerve sprouting induced by botulinum toxin type A. Neural Regen Res (2014) 0.76
Pharmacotherapy for the management of achalasia: Current status, challenges and future directions. World J Gastrointest Pharmacol Ther (2015) 0.75
IGF-1 antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength. Int J Mol Sci (2013) 0.75
Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature (1993) 5.73
Supersensitivity of skeletal muscle produced by botulinum toxin. J Physiol (1960) 3.70
The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. Q J Exp Physiol Cogn Med Sci (1968) 3.16
Pharmacologic weakening of extraocular muscles. Invest Ophthalmol (1973) 2.82
Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol (1985) 2.72
Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A (1999) 1.99
The role of neurotrophic factors in nerve regeneration. Neurosurg Focus (2009) 1.69
Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. J Cell Biol (1990) 1.60
Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris (2001) 1.36
Response and immunoresistance to botulinum toxin injections. Neurology (1995) 1.35
Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology (1988) 1.29
Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience (1990) 1.13
The role of corticotropin-releasing factor in pain and analgesia. Pain (2000) 1.13
Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest Ophthalmol Vis Sci (1990) 1.11
Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol (2009) 1.10
Myofiber length and three-dimensional localization of NMJs in normal and botulinum toxin treated adult extraocular muscles. Invest Ophthalmol Vis Sci (2007) 1.10
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol (1996) 1.08
Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett (1998) 1.08
Role of muscle insulin-like growth factors in nerve sprouting: suppression of terminal sprouting in paralyzed muscle by IGF-binding protein 4. J Cell Biol (1994) 1.07
Presynaptic actions of botulinal neurotoxins at vertebrate neuromuscular junctions. J Physiol (Paris) (1990) 1.07
Regulation of synaptic transmission by CRF receptors. Rev Neurosci (2006) 1.00
Miniature end-plate potentials in rat skeletal muscle poisoned with botulinum toxin. J Physiol (1984) 1.00
How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats. J Orthop Res (2006) 0.97
Signaling by insulin-like growth factors in paralyzed skeletal muscle: rapid induction of IGF1 expression in muscle fibers and prevention of interstitial cell proliferation by IGF-BP5 and IGF-BP4. J Neurosci (1994) 0.95
Relationship of insulin-like growth factor II gene expression in muscle to synaptogenesis. Proc Natl Acad Sci U S A (1989) 0.95
Distinct patterns of motor nerve terminal sprouting induced by ciliary neurotrophic factor vs. botulinum toxin. J Comp Neurol (2007) 0.94
Focal application of neutralizing antibodies to soluble neurotrophic factors reduces collateral axonal branching after peripheral nerve lesion. Eur J Neurosci (2002) 0.91
Axonal branching and recovery of coordinated muscle activity after transection of the facial nerve in adult rats. Adv Anat Embryol Cell Biol (2005) 0.91
Differential spatio-temporal expression of the insulin-like growth factor genes in regenerating sciatic nerve. Brain Res Mol Brain Res (1995) 0.85
Botulinum A toxin injection. Failures in clinical practice and a biomechanical system for the study of toxin-induced paralysis. Ophthal Plast Reconstr Surg (1990) 0.83
Corticotropin-releasing factor in antinociception and inflammation. Eur J Pharmacol (1997) 0.83
Reduction in touch sensitivity and hyperinnervation in vesicant-injured rabbit eyelid by direct injection of corticotropin releasing factor. Neurosci Lett (2006) 0.78
Muscle loss from doxorubicin injections into the eyelids of a patient with blepharospasm. Am J Ophthalmol (1993) 0.77
Myotoxic effects of the skeletal muscle-specific immunotoxin, ricin-mAb35, on orbicularis oculi muscle after eyelid injections in rabbits. Ophthal Plast Reconstr Surg (2004) 0.77
Botulinum toxin pretreatment augments the weakening effect of injection with ricin-mAb35 in rabbit extraocular muscle. J AAPOS (2008) 0.77
Reduction in vesicant-induced cellular inflammation and hyperalgesia by local injection of corticotropin releasing factor in rabbit eyelid. Inflamm Res (2002) 0.77
Neuronal mechanisms contribute to corticotropin-releasing factor-induced anti-oedema effect in the rat hind paw. Neuropeptides (2000) 0.77
Bupivacaine-induced myotoxicity and its effect on botulinum toxin paresis. Ann Plast Surg (2008) 0.76
Advances in methods and algorithms in a modern quantum chemistry program package. Phys Chem Chem Phys (2006) 6.51
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Generalized born model with a simple smoothing function. J Comput Chem (2003) 4.36
Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures. J Comput Chem (2004) 3.83
Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: a SCAI-based survey study of US interventional cardiologists. Catheter Cardiovasc Interv (2013) 2.02
Perioperative visual loss in ocular and nonocular surgery. Clin Ophthalmol (2010) 1.92
Unprotected left main revascularization in patients with acute coronary syndromes. Eur Heart J (2009) 1.66
Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. Ophthalmology (2008) 1.63
Clinical characteristics in 53 patients with cat scratch optic neuropathy. Ophthalmology (2011) 1.62
Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. Eur Heart J (2008) 1.58
Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol (2005) 1.58
Ocular ethambutol toxicity. Mayo Clin Proc (2003) 1.57
Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma. Am J Ophthalmol (2007) 1.56
Gene delivery through cell culture substrate adsorbed DNA complexes. Biotechnol Bioeng (2005) 1.50
Percutaneous left ventricular assist device: "TandemHeart" for high-risk coronary intervention. Catheter Cardiovasc Interv (2005) 1.49
Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis. JACC Cardiovasc Interv (2008) 1.48
Transient homonymous hemianopia and positive visual phenomena in patients with nonketotic hyperglycemia. Arch Ophthalmol (2007) 1.46
False-negative apraclonidine testing in acute Horner syndrome. Can J Ophthalmol (2009) 1.43
Preprocedural white blood cell count as a predictor of death and major adverse cardiac events in patients undergoing percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol (2009) 1.40
Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction. Catheter Cardiovasc Interv (2007) 1.40
Saphenous vein graft intervention: status report 2014. J Invasive Cardiol (2014) 1.39
Percutaneous intervention of left main coronary artery compression by pulmonary artery aneurysm. Catheter Cardiovasc Interv (2010) 1.39
Re-examination of the antithrombotic regimen in the STEMI-RADIAL trial. J Am Coll Cardiol (2014) 1.39
Fibromuscular dysplasia of the left anterior descending coronary artery. JACC Cardiovasc Interv (2012) 1.38
Isolated third, fourth, and sixth cranial nerve palsies from presumed microvascular versus other causes: a prospective study. Ophthalmology (2013) 1.36
Drug-eluting stent fracture: incidence, contributing factors, and clinical implications. Catheter Cardiovasc Interv (2010) 1.32
Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One (2012) 1.30
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
Increased extraocular muscle strength with direct injection of insulin-like growth factor-I. Invest Ophthalmol Vis Sci (2006) 1.23
Crosslinked hyaluronic acid hydrogels: a strategy to functionalize and pattern. Biomaterials (2005) 1.20
The effect of resection on satellite cell activity in rabbit extraocular muscle. Invest Ophthalmol Vis Sci (2006) 1.16
Substrate-mediated delivery from self-assembled monolayers: effect of surface ionization, hydrophilicity, and patterning. Acta Biomater (2005) 1.14
Myofiber length and three-dimensional localization of NMJs in normal and botulinum toxin treated adult extraocular muscles. Invest Ophthalmol Vis Sci (2007) 1.10
Pegylated interferon alpha-associated optic neuropathy. J Neuroophthalmol (2010) 1.06
Extensive antibody cross-reactivity among infectious gram-negative bacteria revealed by proteome microarray analysis. Mol Cell Proteomics (2008) 1.05
Increasing muscle strength as a treatment for strabismus: sustained release of insulin-like growth factor-1 in rabbit extraocular muscle. J AAPOS (2006) 0.99
Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target (2010) 0.99
Optic neuropathy in vitamin B12 deficiency. Eur J Intern Med (2005) 0.97
Transplant coronary artery disease. JACC Cardiovasc Interv (2010) 0.96
Botulinum toxin treatment of extraocular muscles in rabbits results in increased myofiber remodeling. Invest Ophthalmol Vis Sci (2005) 0.95
Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol (2008) 0.94
Calculation of protein heat capacity from replica-exchange molecular dynamics simulations with different implicit solvent models. J Phys Chem B (2008) 0.94
Adult and developmental myosin heavy chain isoforms in soleus muscle of aging Fischer Brown Norway rat. Anat Rec A Discov Mol Cell Evol Biol (2005) 0.92
Posterior vitreous detachment in AION. Ophthalmology (2009) 0.90
Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol (2009) 0.90
Sparing of extraocular muscle in aging and muscular dystrophies: a myogenic precursor cell hypothesis. Exp Cell Res (2011) 0.89
Subconjunctival herniated orbital fat: A benign adipocytic lesion that may mimic pleomorphic lipoma and atypical lipomatous tumor. Am J Surg Pathol (2007) 0.89
Patent foramen ovale: clinical manifestations and treatment. Rev Cardiovasc Med (2008) 0.89
Identification of small-molecule inhibitors of Yersinia pestis Type III secretion system YscN ATPase. PLoS One (2011) 0.89
Occlusive vasculitis in a patient with concomitant West Nile virus infection. Am J Ophthalmol (2003) 0.89
Extraocular muscle force generation after ricin-mAb35 injection: implications for strabismus treatment. J AAPOS (2003) 0.88
FIEFDom: a transparent domain boundary recognition system using a fuzzy mean operator. Nucleic Acids Res (2008) 0.87
Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy. Exp Eye Res (2006) 0.87
Sampling of near-native protein conformations during protein structure refinement using a coarse-grained model, normal modes, and molecular dynamics simulations. Proteins (2008) 0.87
Comparison between self-guided Langevin dynamics and molecular dynamics simulations for structure refinement of protein loop conformations. J Comput Chem (2011) 0.87
Effects of recession versus tenotomy surgery without recession in adult rabbit extraocular muscle. Invest Ophthalmol Vis Sci (2010) 0.87
Structure refinement of protein model decoys requires accurate side-chain placement. Proteins (2012) 0.87
Bimolecular Complementation to Visualize Filovirus VP40-Host Complexes in Live Mammalian Cells: Toward the Identification of Budding Inhibitors. Adv Virol (2011) 0.86
Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. Antimicrob Agents Chemother (2013) 0.86
Can hygroscopic expansion compensate polymerization shrinkage? Part I. Deformation of restored teeth. Dent Mater (2010) 0.86
Comatic aberration as a cause of monocular diplopia. J Cataract Refract Surg (2006) 0.85
The role of Pitx2 in maintaining the phenotype of myogenic precursor cells in the extraocular muscles. PLoS One (2013) 0.85
Histological and morphometric evaluation of transient retinal and optic nerve ischemia in rat. Brain Res (2006) 0.85
Effect of recurrent laryngeal nerve section on the laryngeal muscles of adult rabbits. Otolaryngol Head Neck Surg (2006) 0.85
Ocular and orbital pain for the headache specialist. Curr Neurol Neurosci Rep (2011) 0.85
Another case of leber hereditary optic neuropathy in an octogenarian. J Neuroophthalmol (2009) 0.84
Defining the heterogeneity of skeletal muscle-derived side and main population cells isolated immediately ex vivo. J Cell Physiol (2010) 0.84
Bilateral retinal occlusion progressing to long-lasting blindness in severe preeclampsia. Obstet Gynecol (2002) 0.84
A host-oriented inhibitor of Junin Argentine hemorrhagic fever virus egress. J Virol (2014) 0.83
Treatment of vision loss in giant cell arteritis. Curr Treat Options Neurol (2012) 0.83
Prevalence of optic nerve edema in patients on peripheral hemodialysis. Ophthalmology (2007) 0.83
Effects of elevated thyroid hormone on adult rabbit extraocular muscles. Invest Ophthalmol Vis Sci (2009) 0.83
Acute intermittent porphyria presenting as a diffuse encephalopathy. Ann Neurol (2005) 0.83
Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy. Am J Physiol Heart Circ Physiol (2008) 0.83
Myonuclear addition to uninjured laryngeal myofibers in adult rabbits. Ann Otol Rhinol Laryngol (2005) 0.83
Retinal nerve fiber layer thickness using spectral-domain optical coherence tomography in patients with no light perception secondary to optic atrophy. J Neuroophthalmol (2013) 0.82
Myogenic growth factors can decrease extraocular muscle force generation: a potential biological approach to the treatment of strabismus. Invest Ophthalmol Vis Sci (2008) 0.82
Normal exophthalmometry measurements in a United States pediatric population. Ophthal Plast Reconstr Surg (2012) 0.82
Incidence of ocular injury in visually asymptomatic orbital fractures. Ophthal Plast Reconstr Surg (2009) 0.82
Atypical Leber Hereditary Optic Neuropathy: 18 Year Interval Between Eyes. J Neuroophthalmol (2016) 0.82
Update on thyroid eye disease and management. Clin Ophthalmol (2009) 0.82
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Clin Ophthalmol (2011) 0.82
Myosin heavy chain isoform immunolabelling in diabetic rats with peripheral neuropathy. Acta Histochem (2005) 0.81
Arthroscopic versus open ankle arthrodesis: a retrospective cost analysis. J Foot Ankle Surg (2010) 0.81
Excision of periorbital hemangiomas to correct visual abnormalities. Arch Facial Plast Surg (2011) 0.81
Stent thrombosis with drug-eluting stents: a re-examination of the evidence. Catheter Cardiovasc Interv (2007) 0.81
Gender-related differences of diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents: a real-life multicenter experience. Int J Cardiol (2012) 0.80
Muscle strength following direct injection of doxorubicin into rabbit sternocleidomastoid muscle in situ. Muscle Nerve (2002) 0.80
Lash ptosis in congenital and acquired blepharoptosis. Arch Ophthalmol (2007) 0.80
Percutaneous coronary intervention in nonagenarian: a meta-analysis of observational studies. J Cardiovasc Med (Hagerstown) (2013) 0.80
Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo. Emerg Infect Dis (2014) 0.80
C57BL/6 life span study: age-related declines in muscle power production and contractile velocity. Age (Dordr) (2015) 0.80
Synthesis and characterization of injectable, water-soluble copolymers of tertiary amine methacrylates and poly(ethylene glycol) containing methacrylates. Biomaterials (2002) 0.80
Continuous remodeling of adult extraocular muscles as an explanation for selective craniofacial vulnerability in oculopharyngeal muscular dystrophy. J Neuroophthalmol (2004) 0.80